GeneDx Holdings Corp vs Zeta Global Holdings Corp — how do they compare? GeneDx Holdings Corp trades at $86.53 (market cap $2.56B), while Zeta Global Holdings Corp trades at $30.45 (market cap $7.73B). The key difference: Zeta Global Holdings Corp is far larger — about 3× GeneDx Holdings Corp's market cap, and Zeta Global Holdings Corp is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| WGS | ZETA | |
|---|---|---|
Market Cap | $2.56B | $7.73B |
Sector | Technology | Technology |
52-Week High | $167.51 | $32.68 |
52-Week Low | $34.51 | $14.55 |
Enterprise Value | $2.60B | $7.62B |
Signals from Pluang's Aura AI — not financial advice
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
ZETA trades at $30.79, down 1.79% today but maintains strong institutional support with 75% analyst buy ratings. The stock shows bullish technical signals with consecutive earnings beats and 44% revenue growth in Q2 2026. Recent news highlights AI platform expansion and partnership opportunities driving investor optimism despite negative net margins.
Outlook remains positive with revenue growth accelerating to $1.6B projected for 2026 and consensus price target of $31.19 offering 1.3% upside. Key risks include rich valuation (P/S 4.59x) and execution challenges in competitive marketing tech space, though AI adoption and institutional inflows support bullish thesis.
Trailing returns across standard periods
Latest headlines on both assets
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →